Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Prior to Surgery:~* Body mass index (BMI) of 18.0 to 38.0 kg/m2, inclusive~* Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia (Mayo and popliteal sciatic block) not to include base wedge procedure~After Surgery:~* Subject reported pain of ≥4 on the NPRS, and moderate or severe pain on the Verbal Categorical Rating Scale (VRS) within 9 hours after removal of the popliteal sciatic block on Day 1~* Subject is lucid and able to follow commands~* All analgesic guidelines were followed during and after the bunionectomy~Exclusion Criteria:~Prior to Surgery:~* History in the past 10 years of malignancy, except for squamous cell skin cancer, basal cell skin cancer, and Stage 0 cervical carcinoma in situ~* History of cardiac dysrhythmias requiring anti-arrhythmia treatment(s)~* History of abnormal laboratory results ≥2.5 × upper limit of normal (ULN)~* History of peripheral neuropathy~* A known or clinically suspected infection with human immunodeficiency virus or hepatitis B or C viruses~* Prior medical history of bunionectomy or other foot surgery~* Intolerant of or unwilling to receive hydrocodone, acetaminophen, or ibuprofen~* For female subjects: Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose~* For male subjects: Male subjects with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last study drug dose~After Surgery:~* Subject had a type 3 deformity requiring a base wedge osteotomy or concomitant surgery such as hammertoe repair; or experienced medical complications during the bunionectomy that, in the opinion of the investigator, should preclude randomization~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VX-150 (Type: EXPERIMENTAL): None
- Hydrocodone Bitartrate/Acetaminophen (HB/APAP) (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).